Glenmark Therapeutics Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) in the US market. The product is positioned as an alternative to the active ingredient in MiraLAX® Powder for Solution by Bayer HealthCare LLC.
According to Nielsen® syndicated data, the MiraLAX® Powder for Solution, 17 grams (OTC) market achieved annual sales of approximately $555.7 million for the 52-week period ending February 22, 2025.
Marc Kikuchi, President & Business Head, North America at Glenmark, stated,
“We are excited to announce the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers.”
For more information on the product and purchase details, visit: Glenmark Pharma US.
